2. Academic Validation
  3. The design and development of 2-aryl-2-hydroxy ethylamine substituted 1H,7H-pyrido[1,2,3-de]quinoxaline-6-carboxamides as inhibitors of human cytomegalovirus polymerase

The design and development of 2-aryl-2-hydroxy ethylamine substituted 1H,7H-pyrido[1,2,3-de]quinoxaline-6-carboxamides as inhibitors of human cytomegalovirus polymerase

  • Bioorg Med Chem Lett. 2010 Mar 15;20(6):1994-2000. doi: 10.1016/j.bmcl.2010.01.094.
Steven P Tanis 1,  Joseph W Strohbach,  Timothy T Parker,  Malcom W Moon,  Suvit Thaisrivongs,  William R Perrault,  Todd A Hopkins,  Mary L Knechtel,  Nancee L Oien,  Janet L Wieber,  Kevin J Stephanski,  Michael W Wathen
Affiliations

Affiliation

  • 1 Global Research and Development, Pfizer Inc., San Diego, CA 92121, USA. sptanis@sbcglobal.net
PMID: 20167488 DOI: 10.1016/j.bmcl.2010.01.094
Abstract

Discovery efforts were focused on identifying a non-nucleoside Antiviral for treating infections caused by human cytomegalovirus (HCMV) with equal or better potency and diminished toxicity compared to current therapeutics. This Letter describes the HCMV DNA Polymerase inhibition and in vitro Antiviral activity of various 2-aryl-2-hydroxy ethylamine substituted 1H,7H-pyrido[1,2,3-de]quinoxaline-6-carboxamides.

Figures
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z